» Articles » PMID: 36558775

Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment

Abstract

Multidrug resistance of bacteria has prompted intensive development work on new medicines, but also the search for effective options among the oldest antibiotics. Although intravenous fosfomycin (IVFOS) seems to be an interesting proposal, the recommended agar dilution method for susceptibility determination poses a major problem in routine diagnostic testing. As a consequence, there is a lack of comprehensive data on the frequency of isolation of susceptible or resistant strains. This fact triggered the disposition of EUCAST concerning the revision of IVFOS breakpoints (BPs), including withdrawal of BPs for (excluding ) and coagulase-negative staphylococci. Therefore, the aim of this study was to assess the activity of fosfomycin against numerous clinical strains using recommended methods. : A total of 997 bacterial strains were tested from the following genera: , spp., spp., spp., and spp., for which there are currently no BPs. The strains were isolated from various clinical materials from patients hospitalized in five hospitals. During the investigation, the recommended agar dilution method was used. Susceptibility to other antibiotics and resistance mechanisms were determined using an automatic method (Phoenix) the disk diffusion method, and E-tests. MIC values of fosfomycin were estimated for all strains and for susceptible and multidrug-resistant (MDR) strains individually. : Except for and , 83% of the strains were susceptible to IVFOS, including the largest percentage of and . spp. turned out to be the least susceptible strains (66%). The highest proportion of susceptibility to fosfomycin was found among strains that were sensitive to other antibiotics (80.9%), and the lowest was found among Gram-negative carbapenemase-producing bacteria (55.6%) and ESBL+ bacteria (61.6%). The MIC evaluation revealed the lowest MIC and MIC values for (0.5 mg/L and 1 mg/L, respectively) and (4 mg/L and 32 mg/L, respectively). The highest values of MIC were found for spp. (256 mg/L), while the highest values of MIC were found for spp. and spp. (256 mg/L and 512 mg/L, respectively). : IVFOS appears to be suitable for the treatment of many infections, including the empirical treatment of polymicrobial infections and those caused by MDR strains, since the sensitivity of the studied strains to this antibiotic in different groups ranged from 66% to as much as 99%. Sensitivity to fosfomycin was also demonstrated by 60% of carbapenem-resistant strains; therefore, IVFOS is one of the few therapeutic options that can be effective against the most resistant Gram-negative rods. In light of the general consultation posted by EUCAST, obtaining data such as IVFOS MIC value distributions may be vital for the decision of implementing fosfomycin into breakpoint tables.

Citing Articles

Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections.

Tsilika M, Ntziora F, Giannitsioti E Pathogens. 2025; 14(2).

PMID: 40005507 PMC: 11858038. DOI: 10.3390/pathogens14020130.


Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection of clinical isolates.

Bixby M, Collins L, Daley E, Salay J, Oliver S, Bryson A JAC Antimicrob Resist. 2025; 7(1):dlaf013.

PMID: 39980626 PMC: 11840249. DOI: 10.1093/jacamr/dlaf013.


Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Epidemic Infections in Eastern Europe: A Systematic Literature Review.

Piotrowski M, Alekseeva I, Arnet U, Yucel E Antibiotics (Basel). 2024; 13(10).

PMID: 39452244 PMC: 11505456. DOI: 10.3390/antibiotics13100978.


Resistome in a changing environment: Hotspots and vectors of spreading with a focus on the Russian-Ukrainian War.

Symochko L, Pereira P, Demyanyuk O, Pinheiro M, Barcelo D Heliyon. 2024; 10(12):e32716.

PMID: 39183836 PMC: 11341293. DOI: 10.1016/j.heliyon.2024.e32716.


Evaluation of the susceptibility of clinical isolates of NDM-producing to new antibiotics included in a treatment regimen for infections.

Slabisz N, Lesnik P, Janc J, Fidut M, Bartoszewicz M, Dudek-Wicher R Front Microbiol. 2024; 15:1331628.

PMID: 38646622 PMC: 11027895. DOI: 10.3389/fmicb.2024.1331628.


References
1.
Cao Y, Peng Q, Li S, Deng Z, Gao J . The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic. RSC Adv. 2022; 9(72):42204-42218. PMC: 9088020. DOI: 10.1039/c9ra08299a. View

2.
Williams P . Potential of fosfomycin in treating multidrug-resistant infections in children. J Paediatr Child Health. 2020; 56(6):864-872. DOI: 10.1111/jpc.14883. View

3.
Trautmann M, Meincke C, Vogt K, Ruhnke M . Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics. Infection. 1992; 20(6):350-4. DOI: 10.1007/BF01710683. View

4.
Zirpe K, Mehta Y, Pandit R, Pande R, Deshmukh A, Patil S . A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients. Indian J Crit Care Med. 2021; 25(9):1055-1058. PMC: 8664030. DOI: 10.5005/jp-journals-10071-23958. View

5.
Parisio E, Camarlinghi G, Coppi M, Niccolai C, Antonelli A, Nardone M . Evaluation of the commercial AD fosfomycin test for susceptibility testing of multidrug-resistant Enterobacterales and Pseudomonas aeruginosa. Clin Microbiol Infect. 2020; . DOI: 10.1016/j.cmi.2020.11.029. View